Coral Laboratories Ltd Stock Price Today (NSE: CORALAB)
Fundamental Score
Coral Laboratories Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Coral Laboratories Ltd share price today is ₹577.90, up +3.57% on NSE/BSE as of 7 August 2026. Coral Laboratories Ltd (CORALAB) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹211.79 (Cr). The 52-week high for CORALAB share price is ₹659.00 and the 52-week low is ₹360.00. At a P/E ratio of 13.11x, CORALAB is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 7.88% and a debt-to-equity ratio of 0.02.
Coral Laboratories Ltd Share Price Chart — NSE/BSE Historical Performance
Coral Laboratories Ltd share price chart: -5.60% return over the past month. 52-week high ₹659.00, 52-week low ₹360.00.
Coral Laboratories Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹575.00 | ₹575.50 | ₹552.50 | ₹558.00 | 368.00 (Cr) | |
| ₹575.00 | ₹581.30 | ₹560.00 | ₹562.30 | 167.00 (Cr) | |
| ₹558.15 | ₹575.00 | ₹558.15 | ₹575.00 | 391.00 (Cr) | |
| ₹574.35 | ₹575.00 | ₹555.00 | ₹557.90 | 288.00 (Cr) | |
| ₹583.00 | ₹583.00 | ₹567.00 | ₹574.35 | 387.00 (Cr) | |
| ₹574.45 | ₹583.00 | ₹561.10 | ₹580.00 | 1.28K (Cr) | |
| ₹576.00 | ₹576.00 | ₹547.95 | ₹555.25 | 622.00 (Cr) | |
| ₹556.15 | ₹579.90 | ₹556.15 | ₹576.75 | 982.00 (Cr) | |
| ₹558.05 | ₹579.90 | ₹556.00 | ₹556.15 | 792.00 (Cr) | |
| ₹575.00 | ₹582.00 | ₹560.00 | ₹581.95 | 330.00 (Cr) |
Coral Laboratories Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹574.35 | ₹581.30 | ₹552.50 | ₹558.00 | -2.85% | |
| ₹618.00 | ₹634.90 | ₹547.95 | ₹574.35 | -7.06% | |
| ₹526.00 | ₹659.00 | ₹475.00 | ₹618.00 | +17.49% | |
| ₹427.70 | ₹516.30 | ₹411.10 | ₹473.05 | +10.60% | |
| ₹392.45 | ₹445.00 | ₹373.10 | ₹424.95 | +8.28% | |
| ₹434.00 | ₹472.95 | ₹360.00 | ₹370.55 | -14.62% | |
| ₹436.60 | ₹496.00 | ₹420.10 | ₹443.70 | +1.63% | |
| ₹458.95 | ₹496.60 | ₹415.00 | ₹434.65 | -5.29% | |
| ₹494.90 | ₹504.70 | ₹429.00 | ₹438.50 | -11.40% | |
| ₹511.90 | ₹532.80 | ₹482.50 | ₹490.20 | -4.24% | |
| ₹478.00 | ₹545.00 | ₹478.00 | ₹509.40 | +6.57% | |
| ₹452.73 | ₹543.37 | ₹447.74 | ₹489.15 | +8.05% |
AI Research Briefing
Powered by Gemini · 2026-04-09
Micro-cap pharma play hoping for a turnaround, but financials are deteriorating; avoid until clear signs of improvement.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Coral Laboratories completed capacity expansion at its Dehradun plant. The board re-appointed Mr. Malay Doshi as an Independent Director. Markets Mojo downgraded the stock to a 'Strong Sell'. The stock hit a fresh 52-week low of on March 27, 2026.
CORE STORY (THE REAL GAME)
- Capacity expansion completed
- Low valuation relative to industry
- Bearish technical indicators
- Successful capacity utilization
- Improved quarterly results
- Positive analyst upgrades
- Micro-cap liquidity risk
- Four consecutive quarters of negative results
- Declining sales and profit
- Strong Sell rating
No significant FII/DII activity. Promoter holding stable at 71.51%.
Indian pharma sector projected to grow to $130 billion by 2030, but faces global pricing pressures.
Dehradun plant capacity expansion completed.
Poor, Free Cash Flow 5Y: ₹0.21 Cr.
Next 3-6 months hinge on the company's ability to translate capacity expansion into improved sales and profitability. Failure to do so will likely result in further price decline.
Primary Thesis Risk
Inability to translate capacity expansion into improved financials.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Coral Laboratories Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Coral Laboratories Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of CORALAB across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Strong Operating Margins (15.91%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 13.11 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (54.73%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Conservative Debt Levels (D/E: 0.02)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (135.12x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (71.51%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
6 factors identified
Below-Average Return on Equity (7.88%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Revenue Contraction (-5.87%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Limited Growth History (-2.31% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Earnings Growth (3.60% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (3.60% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Negative Free Cash Flow (₹-4.83 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Coral Laboratories Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Coral Laboratories Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Coral Laboratories LtdCoral Laborator...Selected✓ CORALAB • 524506 | 44.7/100 | ₹577.90₹578 | ₹211.79₹211.79 | 13.11Average 13.1 Average | 7.88%Poor 7.88% Poor | 10.99%Average 10.99% Average | 0.02Excellent 0.0 Excellent | 3.60%Average 3.60% Average | -2.31%Poor -2.31% Poor | 0.25% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Coral Laboratories Ltd PE Ratio History
Historical price-to-earnings ratio for CORALAB — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹44.19 | ₹762.85 | 17.3x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Coral Laboratories Ltd Dividend History
Annual cash dividends paid by CORALAB — dividend yield 0.25%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹0.71 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Coral Laboratories Ltd Quarterly Performance
Latest quarterly metrics for CORALAB — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-5.87%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
54.73%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
-2.31%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
3.60%
Compounded annual net profit growth over 5 years
Coral Laboratories Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for CORALAB — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Coral Laboratories Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Coral Laboratories Ltd (CORALAB) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Coral Laboratories Ltd
About CORALAB (Coral Laboratories Ltd)
Coral Laboratories Ltd is a dynamic pharmaceutical company dedicated to developing, manufacturing, and marketing a broad spectrum of healthcare solutions. With a strong commitment ...to quality and innovation, Coralab focuses on creating accessible and affordable medicines that address diverse medical needs across various therapeutic areas. Their state-of-the-art manufacturing facilities adhere to the highest international standards, ensuring the production of safe, effective, and reliable pharmaceutical products. Coralab continuously invests in research and development to stay at the forefront of pharmaceutical advancements and deliver innovative solutions that improve patient outcomes. Coralab's comprehensive product portfolio encompasses a wide range of therapeutic categories, catering to both acute and chronic conditions. These include formulations for managing infectious diseases, such as antibiotics and antifungals, as well as treatments for gastrointestinal disorders, pain management, and respiratory ailments. The company also offers a diverse selection of medications for cardiovascular health, diabetes management, and parasitic infections. With a focus on patient well-being, Coralab is committed to providing healthcare professionals and patients with a wide array of treatment options to enhance their quality of life. Coralab operates with a global perspective, serving markets in India and beyond. Through strategic partnerships and a robust distribution network, the company strives to make its pharmaceutical products accessible to patients worldwide. With a strong emphasis on ethical business practices and a customer-centric approach, Coralab aims to build lasting relationships with healthcare providers and stakeholders. Driven by a passion for improving global health, Coralab continues to expand its reach and impact, delivering high-quality pharmaceutical solutions to meet the evolving needs of patients around the world.
Company Details
Key Leadership
Corporate Events
CORALAB Share Price: Frequently Asked Questions
What is the current share price of Coral Laboratories Ltd?
Coral Laboratories Ltd (CORALAB) trades at ₹577.90 on NSE and BSE. Market cap ₹211.79 (Cr). Educational data only.
What is the P/E ratio of Coral Laboratories Ltd?
Coral Laboratories Ltd has a P/E of 13.11x vs industry average 34.89x.
What is the Bull Run score for Coral Laboratories Ltd?
Coral Laboratories Ltd has a Bull Run score of 44.7/100 based on 25+ financial parameters.
Does Coral Laboratories Ltd pay dividends?
Coral Laboratories Ltd has a dividend yield of 0.25%. Past dividends don't guarantee future payments.
What is the ROE of Coral Laboratories Ltd?
Coral Laboratories Ltd has ROE of 7.88%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Coral Laboratories Ltd?
Coral Laboratories Ltd has debt-to-equity of 0.02.
Is Coral Laboratories Ltd a good investment?
Bull Run gives Coral Laboratories Ltd a score of 44.7/100. This is not investment advice — consult a SEBI-registered advisor.